In:
Arteriosclerosis, Thrombosis, and Vascular Biology, Ovid Technologies (Wolters Kluwer Health), Vol. 28, No. 4 ( 2008-04), p. 692-697
Abstract:
We hypothesized that a reduction in the endogenous NOS inhibitor ADMA by overexpression of the DDAH enzyme would increase NO synthesis and thereby enhance insulin sensitivity. In response to a glucose load, the DDAH transgenic mouse manifested greater insulin sensitivity, mediated in part by enhanced hepatic or skeletal muscle response to insulin. ADMA may be a new target for treatment of insulin resistance.
Type of Medium:
Online Resource
ISSN:
1079-5642
,
1524-4636
DOI:
10.1161/ATVBAHA.108.162073
Language:
English
Publisher:
Ovid Technologies (Wolters Kluwer Health)
Publication Date:
2008
detail.hit.zdb_id:
1494427-3